Endonovo Therapeutics (ENDV) Gross Profit (2018 - 2023)
Endonovo Therapeutics has reported Gross Profit over the past 8 years, most recently at $693.0 for Q3 2023.
- Quarterly results put Gross Profit at $693.0 for Q3 2023, down 90.0% from a year ago — trailing twelve months through Sep 2023 was $246034.0 (up 110229.15% YoY), and the annual figure for FY2022 was $125365.0, up 115.7%.
- Gross Profit for Q3 2023 was $693.0 at Endonovo Therapeutics, down from $45200.0 in the prior quarter.
- Over the last five years, Gross Profit for ENDV hit a ceiling of $116597.0 in Q4 2022 and a floor of -$35549.0 in Q4 2020.
- Median Gross Profit over the past 5 years was $33156.0 (2019), compared with a mean of $33164.6.
- Biggest five-year swings in Gross Profit: crashed 135.1% in 2020 and later surged 16828.84% in 2023.
- Endonovo Therapeutics' Gross Profit stood at $101268.0 in 2019, then crashed by 135.1% to -$35549.0 in 2020, then surged by 75.96% to -$8545.0 in 2021, then skyrocketed by 1464.51% to $116597.0 in 2022, then tumbled by 99.41% to $693.0 in 2023.
- The last three reported values for Gross Profit were $693.0 (Q3 2023), $45200.0 (Q2 2023), and $83544.0 (Q1 2023) per Business Quant data.